Hoffmann-La Roche: Arthritis, Rheumatoid trials

The registry lists 219 Arthritis, Rheumatoid studies with Hoffmann-La Roche as lead sponsor. 2 are open to participants now and 139 have results posted.

Phase 1 6Phase 2 22Phase 3 85Phase 4 28No phase 80(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNFCompletedNCT00977106Phase 3Results posted
• A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT00951275Phase 3Results posted
• A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to MethotrexateCompletedNCT00934648Phase 4Results posted
• A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)CompletedNCT00891020Phase 3Results posted
• A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00887341Phase 2Results posted
• An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) TherapyCompletedNCT00883753Phase 3Results posted
• A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid ArthritisCompletedNCT00848120Phase 3Results posted
• A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to MethotrexateTerminatedNCT00845832Phase 2Results posted
• A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDsCompletedNCT00810277Phase 3Results posted
• A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate TreatmentCompletedNCT00810199Phase 3Results posted
• A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or AdalimumabTerminatedNCT00808210Phase 2Results posted
• A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.CompletedNCT00773461Phase 3Results posted
• A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT00754572Phase 3Results posted
• A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.CompletedNCT00754559Phase 3Results posted
• An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.CompletedNCT00750880Phase 3Results posted
• A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid ArthritisCompletedNCT00721123Phase 3Results posted
• An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesCompletedNCT00720798Phase 3Results posted
• A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate TherapyTerminatedNCT00673920Phase 3Results posted
• A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to MethotrexateCompletedNCT00578305Phase 3Results posted
• A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00535782Phase 3Results posted
• A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00531817Phase 3Results posted
• A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.CompletedNCT00504777Phase 4Results posted
• A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.CompletedNCT00503425Phase 3Results posted
• A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.CompletedNCT00502996Phase 3Results posted
• A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.CompletedNCT00502853Phase 4Results posted
• A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.CompletedNCT00502840Phase 3Results posted
• A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)TerminatedNCT00485589Phase 3Results posted
• A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)TerminatedNCT00476996Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha TherapyCompletedNCT00468546Phase 3Results posted
• A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.CompletedNCT00462345Phase 4Results posted
• A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid ArthritisCompletedNCT00443651Phase 3Results posted
• A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.CompletedNCT00424502Phase 4Results posted
• A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)TerminatedNCT00422942Phase 2Results posted
• A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)CompletedNCT00422383Phase 3Results posted
• A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)TerminatedNCT00406419Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid ArthritisCompletedNCT00299130Phase 3Results posted
• A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid ArthritisCompletedNCT00299104Phase 3Results posted
• A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background MethotrexateCompletedNCT00282308Phase 2Results posted
• A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background MethotrexateCompletedNCT00266227Phase 3Results posted
• A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving MethotrexateCompletedNCT00243412Phase 2Results posted
• A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)CompletedNCT00106535Phase 3Results posted
• A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical PracticeCompletedNCT03291457
• An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) TherapyCompletedNCT03155347Phase 3
• Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) TreatmentCompletedNCT03112213
• A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)CompletedNCT02797769
• Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid ArthritisCompletedNCT02721004
• A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)TerminatedNCT02720120Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT02693210Phase 2
• A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.CompletedNCT02679001
• EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid ArthritisCompletedNCT02648035
• A Study on Rheumatoid Arthritis Patients Treated With RituximabCompletedNCT02622503
• A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical PracticeTerminatedNCT02616328
• Study to Describe Real World Drug Retention Rate of the Tocilizumab at One YearCompletedNCT02608112
• A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in AustraliaCompletedNCT02564770
• An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical PracticeCompletedNCT02552940
• A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)CompletedNCT02534311
• Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)CompletedNCT02402686
• Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha BlockerCompletedNCT02322801
• Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical PracticeCompletedNCT02251860
• Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)CompletedNCT02234960
• Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)CompletedNCT02101307
• A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.CompletedNCT02011334Phase 3
• Study of the Treatment of Algerian Patients With Early Rheumatoid ArthritisCompletedNCT02008266
• A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid ArthritisCompletedNCT01952509
• A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid ArthritisCompletedNCT01921478
• U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)CompletedNCT01918267
• A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)WithdrawnNCT01893255
• A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDsWithdrawnNCT01878318Phase 4
• A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid ArthritisCompletedNCT01834807
• A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT01770834
• A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926CompletedNCT01730456Phase 3
• An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)CompletedNCT01667458
• A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)CompletedNCT01649817
• A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (MONACO)TerminatedNCT01643863
• An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis PatientsCompletedNCT01615419
• An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)CompletedNCT01565122
• An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With GlucocorticoidsCompletedNCT01564901
• An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)CompletedNCT01483326
• An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)CompletedNCT01392001
• An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDsCompletedNCT01388309
• An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)CompletedNCT01384461
• An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT01375478
• Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis PatientsCompletedNCT01347983Phase 3
• An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)CompletedNCT01338545
• An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid ArthritisCompletedNCT01337388
• An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid ArthritisCompletedNCT01283399
• An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid ArthritisTerminatedNCT01277328
• Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis PatientsCompletedNCT01258712Phase 3
• A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid ArthritisCompletedNCT01225393Phase 2
• A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid ArthritisCompletedNCT01214733Phase 3
• An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)TerminatedNCT01196780
• An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)Status unknownNCT01194401
• A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)TerminatedNCT01117129Phase 4
• An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)CompletedNCT01075477
• A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid ArthritisCompletedNCT00965653Phase 1
• A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid ArthritisCompletedNCT00888745Phase 1
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid ArthritisTerminatedNCT00779220Phase 2
• A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid ArthritisTerminatedNCT00718588Phase 1
• A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)CompletedNCT00661284
• A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.CompletedNCT00576433Phase 4